Chimeric antigen receptor T cell treatment in hematologic malignancies

GÖKER H., Malkan Ü. Y., DEMİROĞLU H., BÜYÜKAŞIK Y.

TRANSFUSION AND APHERESIS SCIENCE, cilt.54, sa.1, ss.35-40, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 54 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.transci.2016.01.011
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.35-40
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Adoptive transfer of T cells that have genetically engineered chimeric antigen receptors (CARs) is an encouraging treatment modality in the hematological malignancies. These T cells are capable of selectively recognizing tumor -associated antigens. There are a variety of reported, as well as ongoing studies on the utilization of CART cells in the treatment of leukemia, myeloma, as well as B and T cell lymphomas. In this review, we aimed to highlight current understanding of this promising treatment modality, including its efficacy and adverse effects. (c) 2016 Elsevier Ltd. All rights reserved.